Prion test to avoid doxorubicin resistance in triple negative breast cancer

Queensland researchers believe they have uncovered a mechanism to explain resistance to doxorubicin chemotherapy in patients with triple negative breast cancer. They have found that the drug is sequestered by secreted cellular prion protein (PrPC), which prevents doxorubicin from entering the nuclei of target cells and thus blocks its cytotoxic activity. This raises the possibility ...

Already a member?

Enter your email to keep reading.